Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 2 study of nivolumab in relapsed or refractory primary central nervous system or testicular lymphoma
MOH_2017-02-19_000118Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in primary central nervous system lymphoma (PCNSL) and testicular lymphoma (PTL), sponsored by Bristol Myers Squibb. Primary endpoint: Positive response rate. Status: completed.
02
Drugs
03
Conditions
primary central nervous system lymphoma (PCNSL)testicular lymphoma (PTL)
Beyond the preview
Go deeper on MOH_2017-02-19_000118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-02-19_000118.